rabeprazole sodium + Placebo

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Symptomatic Gastroesophageal Reflux Disease (sGERD)

Conditions

Symptomatic Gastroesophageal Reflux Disease (sGERD)

Trial Timeline

Jan 1, 2009 → Oct 1, 2009

NCT ID

NCT00911534

About rabeprazole sodium + Placebo

rabeprazole sodium + Placebo is a phase 3 stage product being developed by Eisai for Symptomatic Gastroesophageal Reflux Disease (sGERD). The current trial status is completed. This product is registered under clinical trial identifier NCT00911534. Target conditions include Symptomatic Gastroesophageal Reflux Disease (sGERD).

What happened to similar drugs?

3 of 16 similar drugs in Symptomatic Gastroesophageal Reflux Disease (sGERD) were approved

Approved (3) Terminated (4) Active (9)

❌Sodium hyaluronate + placebo injectionDaiichi SankyoPhase 3

🔄ISV-305Sun PharmaceuticalPhase 3

🔄Esomeprazole + Matching placeboAstraZenecaPhase 3

🔄Pasireotide + OctreotideNovartisPhase 3

✅valsartanNovartisApproved

🔄Apixaban + Standard of carePfizerPhase 3

❌Azithromycin plus chloroquinePfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00911534	Phase 3	Completed	Jan 1, 2009	Oct 1, 2009	Symptomatic Gastroesophageal Reflux Disease (sGERD)
NCT00236197	Phase 3	Completed	Oct 1, 2005	Jun 1, 2008	Heartburn

Competing Products

20 competing products in Symptomatic Gastroesophageal Reflux Disease (sGERD)

See all competitors

Product	Company	Stage	Hype Score
Sodium hyaluronate + placebo injection	Daiichi Sankyo	Phase 3	32
ISV-305	Sun Pharmaceutical	Phase 3	40
Verinurad + Febuxostat + Dapagliflozin	AstraZeneca	Phase 2	35
RDEA3170 + Febuxostat + Benzbromarone	AstraZeneca	Phase 1/2	32
Esomeprazole + Matching placebo	AstraZeneca	Phase 3	40
DFV890 + Placebo	Novartis	Phase 2	35
Omalizumab + Omalizumab + Placebo	Novartis	Phase 2	35
Pasireotide + Octreotide	Novartis	Phase 3	40
Tegaserod	Novartis	Phase 2	35
valsartan	Novartis	Approved	43
Atorvastatin - Cholestyramine - Sitosterol	Pfizer	Pre-clinical	26
Epoetin biosimilar	Pfizer	Pre-clinical	26
Apixaban + Standard of care	Pfizer	Phase 3	40
Azithromycin plus chloroquine	Pfizer	Phase 3	32
Mavacamten	Bristol Myers Squibb	Approved	50
Aficamten + Placebo	Sanofi	Phase 3	44
Vandetanib 300 mg	Sanofi	Pre-clinical	26
REGN7508 + Acetylsalicylic Acid (ASA) + Placebo	Regeneron Pharmaceuticals	Phase 3	47
Rivaroxaban + Placebo	Bayer	Phase 3	37
Droxidopa capsules + Placebo capsules	Lundbeck	Approved	40